Search Results
Dec 17, 2025, 18:49 ET U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.American Cancer Society. Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early
More news about: Johnson & Johnson
Dec 17, 2025, 15:29 ET 2G Energy Inc. presentará el nuevo DR aura 412 en POWERGEN 2026
https://mma.prnewswire.com/media/1701284/5684667/2G_High_Res_Logo_Logo.jpg FUENTE 2G Energy
More news about: 2G Energy
Dec 17, 2025, 09:15 ET 2G Energy Inc. to Debut New DR aura 412 at POWERGEN 2026
https://mma.prnewswire.com/media/1701284/2G_High_Res_Logo_Logo.jpg SOURCE 2G Energy
More news about: 2G Energy
Dec 17, 2025, 08:58 ET Samson Sky CEO Receives Global Innovator Award at Congressional Ceremony on Capitol Hill
Gallegos 916-769-6979 (Mobile)[email protected] Additional Hi-Res images available by request
More news about: Samson Sky
Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 2016;76(10):3003-13.viii PADCEV [package insert]. Northbrook, IL: Astellas Pharma US, Inc.
More news about: Astellas Pharma Inc.
Dec 16, 2025, 15:00 ET Puerto Rican street-festival vibes and major prizes mark the 10th Anniversary of Jackpot del Encanto™ in Puerto Rico
Link to High-Res Photos and VideoThroughout its ten-year trajectory and with a network of 19 casinos across the island, Jackpot del Encanto has
More news about: Aristocrat Gaming
Dec 16, 2025, 09:00 ET Introducing the moto g power - 2026: Where design meets durability
direct sunlight. Complementing the visual experience, the new moto g power delivers exceptional audio performance through stereo speakers enhanced by Hi-Res Audio.3 The device also features Dolby Atmos®, which provides rich, immersive sound that brings music, movies, and games to life.Built
More news about: Motorola Mobility, Inc
Dec 15, 2025, 18:43 ET AMERICA'S AUTOMOTIVE TRUST OPENS REFRESHED ROUTE 66 EXHIBITION IN ANTICIPATION OF THEIR UPCOMING DRIVE HOME
Folder of hi-res refreshed Route 66 exhibition imagesAbout America's Automotive TrustAmerica's Automotive Trust works to preserve America's
More news about: America's Automotive Trust
Dec 12, 2025, 20:25 ET U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. J Pathol Clin Res. 2021;7(4):311-325. doi:10.1002/cjp2.203
More news about: Johnson & Johnson
Dec 11, 2025, 12:00 ET bluSONIL Launches Flagship Longevity, Wellness, and Regenerative Aesthetics Studio in Scottsdale
www.blusonil.com.Please find high-res images
More news about: bluSONIL
Dec 11, 2025, 09:00 ET Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
https://doi.org/10.1016/j.cell.2015.11.050 Hudecova et al, Genome Res. 2022 Feb;32(2):215-227. doi: 10.1101/gr.275691.121.Fang et
More news about: VolitionRx Limited
Dec 11, 2025, 08:31 ET Saudi Aviation Club Partners with Switchblade Flying Car Manufacturer to Further Saudi Vision 2030
Gallegos 916-769-6979 (Mobile)[email protected] Additional Hi-Res images available by request
More news about: Samson Sky
Dec 10, 2025, 14:16 ET Menarini Group apresenta os dados da fase 2 da combinação de elacestranto (ORSERDU®) em pacientes com câncer de mama metastático (mBC) ER+, HER2- no San Antonio Breast Cancer Symposium 2025 (SABCS)
hematológicos.[1]Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
hematológicos.[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 13:06 ET Hundreds of Rare Signed HOF Baseball Postcards Hits Market with Ty Cobb, Cy Young, Honus Wagner
Contact:[email protected](800) 560-3272Hi-Res Images Available
More news about: Auction Monthly
Dec 10, 2025, 10:11 ET Menarini Group、2025年サンアントニオ乳がんシンポジウムにてエラセストラント（ORSERDU®）併用療法の第2相データをER+、HER2-転移性乳がん（mBC）患者を対象に発表
Res（2025年）。https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-3033/768341/Clinical-and-Genomic-Factors-Associated-with[2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 07:57 ET Essity destaca avanços ambientais com 98% dos resíduos de produção reciclados na planta de Jarinu
https://mma.prnewswire.com/media/2842611/FOTO_ESSITY_Planta_da_Essity_em_Jarinu_recicla_98_dos__res_duos_industriais_e_a.jpg
More news about: Essity
Dec 09, 2025, 23:19 ET Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025
ematologici.[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 16:00 ET Cirius Therapeutics to Highlight Cardiometabolic Benefits of CIR-0602K at Global Cardiovascular Clinical Trialists (CVCT) Forum 2025
2 Harrison, et al., J Hepat, 2020; 3 Despres, et al., NEJM, 1996; 4 Kumar, et al., Diab Vasc Dis Res, 2019; 5 Harrison, et al., Hepat, 2024; 6 Abufarha, et al., ADA Scientific Sessions, 2025; 7Abufarha, et al.,
More news about: Cirius Therapeutics
Dec 09, 2025, 15:39 ET HitPaw VikPea Launches V5.1.0: Unveiling AI Video Generator, AI Generative Model, and Enhanced Frame Interpolation for Next-Level Video Creation
and noise reduction for low-res videosImproved handling of film and VHS sourcesBest ForFilm restorers, archivists, and content creators working with old footageUsers seeking to restore and enhance vintage or low-res video sourcesCloud-only
More news about: HitPaw. Co., Ltd
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
作多項標籤擴展研究，並為實體癌症和血液系統癌症病人的其他候選藥物，擁有處於不同研發階段的廣泛臨床管線。[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 14:18 ET LG UNVEILS NEW ERA OF LUXURY HOME CINEMA WITH LG MAGNIT 'ACTIVE MICRO LED' DISPLAY
here. For high-res images, click
More news about: LG Electronics USA
Dec 09, 2025, 12:00 ET TrilliumBiO and Oncobit Partner to Bring Novel Uveal Melanoma Monitoring Solution to the U.S.
al. Immuno-Oncology and Technology. 2025;28(C):101079. doi:10.1016/j.iotech.2025.101079.2 Machiraju D, et al. J Exp Clin Cancer Res. 2025;44:213. doi:10.1186/s13046-025-03451-2.3 Ramelyte E, Koett, J, et al. Clinical Cancer Research. Accepted.TrilliumBiO
More news about: TrilliumBiO
Dec 09, 2025, 11:38 ET El Grupo Menarini presenta datos de la combinación de fase 2 de Elacestrant (ORSERDU®) en cáncer de mama
hematológicos.[1] Lloyd et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:49 ET 메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표
변이 전이성 유방암에서 엘라세스트란트 치료 성과와 관련된 임상•유전체 요인(Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer). Clin Cancer Res(2025).
More news about: Menarini Industrie Farmaceutiche Riunite